CAMP signalling in the normal and tumorigenic pituitary gland

Molecular and Cellular Endocrinology

Volumn 392, Issue 1-2, 2014, Pages 37-50

  Formosa, R ^a   Vassallo, J ^a  

^a UNIVERSITY OF MALTA   (Malta)

Author keywords

Adenoma; CAMP; Pituitary hormones; Secondary signalling; Tumorigenesis

Indexed keywords

CYCLIC AMP; GUANINE NUCLEOTIDE BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE TYPE I ALPHA REGULATORY SUBUNIT; RAF PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

CARCINOGENESIS; CELL PROLIFERATION; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HYPOPHYSIS TUMOR; NONHUMAN; PACAP GENE; PRIORITY JOURNAL; PRKAR1A GENE; REGULATORY MECHANISM; REVIEW; TUMOR GROWTH; ANIMAL; BIOLOGICAL MODEL; HYPOPHYSIS; METABOLISM; PATHOLOGY; SECOND MESSENGER; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOGENESIS; CYCLIC AMP; HUMANS; MODELS, BIOLOGICAL; PITUITARY GLAND; SECOND MESSENGER SYSTEMS; SIGNAL TRANSDUCTION;

EID: 84901649596     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.05.004     Document Type: Review

References (185)

1. Adams E.F., Brockmeier S., Friedmann E., Roth M., Buchfelder M., Fahlbusch R. Clinical and biochemical characteristics of acromagalic patients harbouring GNAS-positive and GNAS-negative pituitary tumors. Neurosurgery 1993, 333(2):198-203.
2. Almeida M.Q., Muchow M., Boikos S., Bauer A.J., Griffin K.J., Tsang K.M., Cheadle C., Watkins T., Wen F., Storost M.F., Bossis I., Nesterova M., Stratakis C.A. Mouse Prkar1a haploinsufficientcy leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papilloma by dysregulation of the cell cycle and Wnt signalling. Hum. Mol. Genet. 2010, 19(8):1387-1398.
3. Amar A.P., Weiss M.H. Pituitary anatomy and physiology. Neurosirg. Clin. N. Am. 2003, 14(1):11-23.
4. Andersson P., McGuire J., Rubio C., Gradin K., Whitelaw M.L., Pettersson S., Hanberg A., Poellinger L. A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc. Natl. Acad. Sci. USA 2002, 99(15):9990-9995.
5. Back N., Soinila S. Regulation of secretory granule formation in chronically hypersecretory melanotrophs in the rat pituitary. Cell Tissue Res. 1994, 275:339-344.
6. Back N. The effect of bromocriptine on the intermediate lobe of the rat pituitary: an electron-microscopic, morphometric study. Cell Tissue Res. 1989, 255:405-410.
7. Barlier A., Pellegrini-Bouiller I., Gunz G., Zamora A.J., Jaquet P., Enjalbert A. Impact of GNAS oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J. Clin. Endocrinol. Metab. 1999, 84(8):2759-2765.
8. Beischlag T.V., Morales J.L., Hollingshead B.D., Perdew G.H. The aryl hydrocarbon receptor complex and the control of gene expression. Crit. Rev. Eukaryot. Gene Expr. 2008, 18(3):207-250.
9. Ben-Shlomo A., Pichurin O., Barshop N.J., Wowrowsky K.A., Taylor J., Culler M.D., Chesnokova V., Liu N.A., Melmed S. Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. Mol. Endocrinol. 2007, 21(10):2565-2578.
10. Ben-Shlomo A., Zhou C., Pchurin O., Chesnokova V., Liu N.A., Culler M.D., Melmed S. Constitutive somatostatin receptor activity determines tonic pituitary cell response. Mol. Endocrinol. 2009, 23(3):337-348.
11. Bertherat J., Chanson P., Montminy M. The cyclic adenosine 30,50-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol. Endocrinol. 1995, 9:777-783.
12. Bertherat J., Groussin L., Sandrini F., Matyakhina L., Bei T., Stergiopoulos S., Papageorgiou T., Bourdeau I., Kirschner L.S., Vincent-Dejean C., Perlemoine K., Gicquel C., Bertagna X., Stratakis C.A. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res. 2003, 63:5308-5319.
13. Bertherat J., Horvath A., Groussin L., Grabar S., Boikos S., Cazabat L., Libe R., Rene-Corail F., Stergiopoulos S., Bourdeau I., Bei T., Clauser E., Calendar A., Kirschner L.S., Bertagna X., Carney J.A., Stratakis C.A. Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate -dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. JCEM 2009, 94(6):2085-2091.
14. Bilezikijian L.M., Vale W.W. Stimulation of adenosine 39,59-monophosphate production by growth hormone -releasing factor and its inhibition by somatostatin in anterior pituitary cells in vitro. Endocrinology 1983, 113:1726-1731.
15. Boggild M.D., Jenkinson S., Pistorello M., Boscaro M., Scanarini M., McTernan P., Perrett C.W., Thakker R.V., Clayton R.N. Molecular genetic studies of sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 1994, 78:387-392.
16. Bolander F.F. Molecular Endocrinology 2004, Elvisier Academic Press, USA.
17. Bolger G.B., Erdogan S., Jones R.E., Loughney K., Scotland G., Hoffmann R., Wilkinson I., Farrell C., Houslay M.D. Characterisation of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem. J. 1997, 328:539-548.
18. Bolger G.B., Peden A.H., Steele M.R., MacKenzie C., McEwan D.G., Wallace D.A., Huston E., Baillie G.S., Houslay M.D. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J. Biol. Chem. 2003, 278:33351-33363.
19. Boynton A.L., Whitfield I.F. The role of cyclic AMP in cell proliferation. Adv. Cyclic Nucleotide Res. 1983, I5:195-294.
20. Braeuning A., Kohle C., Buchmann A., Schwarz M. Coordinate regulation of cytochrome P450 1a1 expression in mouse liver by the aryl hydrocarbon receptor and the beta-catenin pathway. Toxicol Sci 2011, 122(1):16-25.
21. Buchfelder M., Fahlbusch R., Merz T., Symowski H., Adams E.F. Clinical correlated in acromegalic patients with pituitary tumors expressing GNAS oncogenes. Pituitary 1999, 1(3-4):181-185.
22. Cadigan K.N., Nusse R. Wnt signalling: a common theme in animal development. Genes Dev. 1997, 11:3286-3305.
23. Cali J.J., Zwaagstra J.C., Mons N., Cooper D.M.F., Krupinski J. Type VIII adenylyl cyclase: a Ca2+/calmodulin-stimulated enzyme expressed in discrete regions of rat brain. J. Biol. Chem. 1994, 269:12190-12195.
24. Canny B.J., Rawlings S.R., Leong D. Pituitary adenylate cyclase-activating polypeptide specifically increases cytosolic calcium ion concentration in rat gonadotropes and somatotropes. Endocrinology 1992, 130:211-215.
25. Carney J.A., Gordon H., Carpenter P.C., Shenoy B.V., Go V.L. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 1985, 64:270-283.
26. Cazabat L., Bouligand J., Salenave S., Bernier M., Gaillard S., Parker F., Young J., Giouchon-Mantel A., Chanson P. Germ-line AIP mutation in apparently sporadic pituitary adenomas: prevalence in a prospective single-centre cohort of 443 patients. J. Clin. Endocrinol. Metab. 2012, 97(4):E663-E670.
27. Chen A.E., Ginty D.D., Fan C.M. Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins. Nature 2005, 433(7023):317-322.
28. Cheng X., Ji Z., Tsalkova T., Mei F. Epac and PKA: a tale of two intracellular cAMP receptors. Acta Biochim. Biophys. Sin. (Shanghai) 2008, 40(7):651-662.
29. Chesire D.R., Dunn T.A., Ewing C.M., Luo J., Isaacs W.B. Identification of aryl hydrocarbon receptor as a putative Wnt/β-catenin pathway target gene in prostate cancer cells. Cancer Res 2004, 64:2523-2533.
30. Christophe J. Type I receptors for PACAP (a neuropeptide even more important than VIP?). Biochim. Biophys. Acta 1993, 1154:183-199.
31. Ciullo I., Diez-Roux G., Di Domenico M., Migliaccio A., Avvedimento E.V. CAMP signalling influences Ras effectors pathways. Oncogene 2001, 20(10):1186-1192.
32. Cochilla A.J., Angelson J.K., Betz W.J. Differential regulation of granule-to-granule and granule-to-plasma membrane fusion during secretion from rat pituitary lactotrophs. J. Cell. Biochem. 2000, 150(4):839-848.
33. Colledge M., Scott J.D. AKAPs: from structure to function. Trends Cell Biol. 1999, 9(6). 219-212.
34. Conti M., Richter W., Mehats C., Liver G., Park J.Y., Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J. Biol. Chem. 2003, 278(8):5493-5496.
35. Corbin J.D., Keely S.L., Park C.R. The distribution and dissociation of cyclic adenosine 3':5'-monophosphate-dependent protein kinases in adipose, cardiac, and other tissues. J. Biol. Chem. 1975, 250:218-225.
36. Cosentino C., Di Domenico M., Porcellini A., Cuozzo C., De Gregorio G., Santillo M.R., Agnese S., Di Stasio R., Feliciello A., Migliaccio A., Avvenimento E.V. P85 regulatory subunit of PI3K mediates cAMP-PKA and estrogens biological effects on growth and survival. Oncogene 2007, 26(14):2095-2103.
37. Daly A., Tichomirowa M., Petrossians P., Heliovaara E., Jefrrain-Rea M., Barlier A., Naves L.A., Ebeling T., Harhu A., Raappana A., Cazabat L., De Menis E., Montañana C.F., Raverot G., Weil R.J., Sane T., Maiter D., Neggers S., Yaneva M., Tabarin A., Verrua E., Eloranta E., Murat A., Vierimaa O., Salmela P.I., Emy P., Toledo R.A., Sabaté M.I., Villa C., Popelier M., Salvatori R., Jennings J., Longás A.F., Labarta Aizpún J.I., Georgitsi M., Paschke R., Ronchi C., Valimaki M., Saloranta C., De Herder W., Cozzi R., Guitelman M., Magri F., Lagonigro M.S., Halaby G., Corman V., Hagelstein M.T., Vanbellinghen J.F., Barra G.B., Gimenez-Roqueplo A.P., Cameron F.J., Borson-Chazot F., Holdaway I., Toledo S.P., Stalla G.K., Spada A., Zacharieva S., Bertherat J., Brue T., Bours V., Chanson P., Aaltonen L.A., Beckers A. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J. Clin. Endocrinol. Metab. 2010, 95:E373-E383.
38. De Gregorio G., Coppa A., Cosentino C., Ucci S., Messina S., Nicolussi A., D'Inzeo S., DiPardo A., Avvendimento E.V., Porcellini A. The p85 regulatory subunit or PI3K mediates TSH-cAMP-PKA growth and survival signals. Oncogene 2007, 26(14):2039-2047.
39. De Oliviera S.K., Hoffmeister M., Gambaryan S., Muller-Esterl W., Guimaraes J.A., Smolenski A.P. Phosphodiesterase 2A forms a complex with the Co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. J. Biol. Chem. 2007, 282(18):13656-13663.
40. de Rooij J., Zwartkruis F.J., Verheijen M.H., Cool R.H., Nijman S.M., Wittinghofer A., Bos J.L. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998, 396:474-477.
41. Delghandi M.P., Johannessen M., Moens U. The cAMP signalling pathway activates CREB through PKA, p38, and MSK1 in NIH 3T3 cells. Cell. Signal. 2005, 17(11):1343-1351.
42. Du K., Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J. Biol. Chem. 1998, 273(49):32377-32379.
43. Dumas N., Marais R. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways: based on the anniversary prize of the Gesellschaft für Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS 2005, 272(14):3491-3504.
44. Dworakowska D., Grossman A.B. The pathophysiology of pituitary adenomas. Best Prac. Res. Clin. Endocrinol. Metab. 2009, 23(5):525-541.
45. Dworakowska D., Wlodek E., Leontiou C.A., Igreja S., Cakir M., Teng M., Prodromou N., Goth M.I., Grozinsky-Glasberg S., Gueorguiev M., Kola B., Korbonits M., Grossman A.B. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr. Relat. Cancer 2009, 16(4):1329-1338.
46. Elston M.S., Gill A.J., Conaglen J.V., Clarkson A., Shaw J.M., Law A.J.J., Cook R.J., Little N.C., Clifton-Bligh R.J., Robinson B.G., McDonald K.L. Wnt pathway inhibitors are strongly down-regulated in pituitary tumours. Endocrinology 2008, 149(2):1235-1242.
47. Englaro W., Rezzeonico R., Durand-Clement M., Lallemand D., Ortonne J.P., Ballotti R. Mitogen-activated protein kinase pathway and AP-1 are activated during cAMP-induced melanogenesis in B-16 mealanoma cells. J. Biol. Chem. 1995, 270:24315-24320.
48. Ewing I., Pedder-Smith S., Franchi G., Riscica M., Emery M., Vax V., Garcia E., Czirjak S., Hanzely Z., Kola B., Korbonits M., Grossman A.B. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin. Endocrinol. 2007, 66:348-352.
49. Faglia G., Arosia M., Spada A.F. GS protein mutations and pituitary tumors: functional correlates and possible therapeutic implications. Metabolism 1996, 45(8):117-119.
50. Farrell W.E., Clayton R.N. Molecular pathogenesis of pituitary tumours. Front. Neuroendocrinol. 2000, 21:174-198.
51. Feinstein W.P., Zhu B., Leavesley S.J., Sayner S.L., Rich T.C. Assessment of cellular mechanisms contributing to cAMP compartmentalization in pulmonary microvascular endothelial cells. Am. J. Physiol.-Cell Physiol. 2012, 302:C839-C852.
52. Formosa R., Gruppetta M., Falzon S., Santillo G., DeGaetano J., Xuereb-Anastasi A., Vassallo J. Expression and clinical significance of Wnt players and survivin in pituitary tumours. Endocr. Pathol. 2012, 23(2):123-131.
53. Formosa, R., Xuereb-Anastasi, A., Vassallo, J., 2013. AIP regulates cAMP signalling and growth hormone secretion in GH3 cells. Endocr. Relat. Cancer. (Epub ahead of printing).
54. Gallegos T.F., Kouznetsova V., Kudlicka K., Sweeney D.E., Bush K.T., Willert K., Farquhar M.G., Nigam S.K. A protein kinase A and Wnt-dependant network regulating an intermediate stage in epithelial tubulogenesis during kidney development. Dev. Biol. 2012, 364(1):11-21.
55. Gao Z., Chen T., Weber M.J., Linden J. A2B adenosine and P2Y2 receptors stimulate mitogen-activated protein kinase in human embryonic kidney-293 cells. Cross-talk between cyclic AMP and protein kinase C pathways. J. Biol. Chem. 1999, 274:5972-5980.
56. Gardner D.G., Shoback D. Greenspan's Basic & Clinical Endocrinology 2007, McGrawHill, USA. eight ed.
57. Gaujoux S., Tissier F., Groussin L., Libe R., Ragazzon B., Launay P., Audebourg A., Dousset B., Bertagna X., Bertherat J. Wnt/B-catenin and 3',5'-cyclic adenosine 5'-monophsophate/protein kinase A signaling pathways alterations and somatic B-catenin gene mutations in the progression of Adenocorticoid Tumours. J. Clin. Endocrin. Metab. 2008, 93(10):4135-4140.
58. Gerits N., Kostenko S., Shiryaev A., Johannessen M., Moens U. Relations between the mitogen-activated protein kinase and cAMP -dependant protein kinase pathways: comradeship and hostility. Cell. Signal. 2008, 20(9):1592-1607.
59. Giannattasio G., Bianchi R., Spada A., Vallar L. Effect of calcium on adenylate cyclase of rat anterior pituitary gland. Endocrinology 1987, 120:2611-2619.
60. Giles A., Madec F., Friedrichsen S., Featherstone K., Chambers T., Harper C.V., Resch J., Brabant G., Davis J.R. Wnt signalling in estrogen-induced lactotroph proliferation. J. Cell Sci. 2011, 124(Pt4):540-547.
61. Gilman A.G. Regulation of adenylyl cyclase by G proteins. Adv. Second Messenger Phosphoprotein Res. 1990, 24:51-57.
62. Gotoh J., Obata M., Yoshie M., Kasai S., Ogawa K. Cyclin D1 over-expression correlates with β-catenin activation, but not with H-ras mutations, and phosphorlation of Akt, GSK3β and ERK1/2 in mouse hepatic carcinogenesis. Carcinogenesis 2003, 24(3):435-442.
63. Gracia-Navarro F., Lamacz M., Tonon M.C., Vaudry H. Pituitary adenylate cyclase-activating polypeptide stimulates calcium mobilization in amphibian pituitary cells. Endocrinology 1992, 131:1069-1074.
64. Greene E.L., Horvath A.D., Nesterova M., Giatzakis C., Bossis I., Stratakis C.A. In vitro functional studies of naturally occurring pathogenic PRKAR1A mutations that are not subject to nonsense mRNA decay. Hum. Mutat. 2008, 29:633-639.
65. Groussin L., Kirschner L.S., Vincent-Dejean C., Perlemoine K., Jullian E., Delemer B., Zacharieva S., Pignatelli D., Carney J.A., Luton J.P., Bertagna X., Stratakis C.A., Bertherat J. Molecular analysis of the cyclic AMP-dependant protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signalling is associated with adrenal tumorigenesis in PPNAD. Am. J. Hum. Genet. 2002, 71(6):1433-1442.
66. Hagen T., Cross D.A., Culbert A.A., West A., Frame S., Morrice N., Reith A.D. FRAT1, a substrate -specific regulator of glycogen synthase kinase-3 activity, is a cellular substrate of protein kinase A. J. Biol. Chem. 2006, 281(46):35021-35029.
67. Ham J., Ivan M., Wynford-Thomas D., Scanlon M.F. GH3 cells expressing constitutively active Gsα (Q227L) show enhanced hormone secretion and proliferation. Mol. Cell. Endocrinol. 1997, 127(1):41-47.
68. Hansen C., Howlin J., Tengholm A., Dyachok O., Vogel W.F., Naim A.C., Greendard P., Andersson T. Wnt5a-induced phosphorylation of DARPP-32 inhibits breast cancer cell migration in a CREB-dependant manner. J. Biol. Chem. 2009, 284(40):27533-27543.
69. Harris B.A. Complete cDNA sequence of a human stimulatory GTP-binding protein alpha subunit. Nucleic Acids Res. 1988, 16(8):3585.
70. Hayward B.E., Barlier A., Korbonits M., Grossman A.B., Jacquet P., Enjalbert A., Bonthron D.T. Imprinting of the Gsα gene GNAS1 in the pathogenesis of acromegaly. J. Clin. Invest. 2001, 107:R31-R36.
71. Heaney A.P. Pituitary tumour pathogenesis. Br. Med. Bull. 2006, 75-76:81-97.
72. Heisler S., Reisine T.D., Hook V.Y., Axelrod J. Somatostatin inhibits multireceptor stimulation of cyclic AMP formation and corticotropin secretion in mouse pituitary tumor cells. Proc. Natl. Acad. Sci. USA 1982, 79(21):6502-6506.
73. Hibberts N.A., Simpson D.J., Bicknell J.E., Broome J.C., Hoban P.R., Clayton R.N., Farrell W.E. Analysis of Cyclin D1 (CCND1) Allelic Imbalance and Overexpression in sporadic Human Pituitary Tumors. Clin. Cancer Res. 1999, 5:2133-2139.
74. Hino S., Tanji C., Nakayama K.I., Kikuchi A. Phosphorylation of β-catenin by cyclic AMP-dependant protein kinase stabilizes β-catenin through inhibition of its ubiquitination. Mol. Cell. Biol. 2005, 25(20):9063-9072.
75. Hoffmann R., Baillie G.S., MacKenzie S.J., Yarwood S.J., Houslay M.D. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J. 1999, 18:893-903.
76. Hollingshead M.C., Patel R.D., Perdew G.H. Endogenous hepatic expression of the hepatitis B virus X-associated protein 2 is adequate for maximal association with aryl hydrocarbon receptor-90-kDa heat shock protein complexes. Mol. Pharmacol. 2006, 70(6):2096-2107.
77. Horvath A., Boikos S., Giatzakis C., Robinson -White A., Groussin L., Griffin K.J., Stein E., Levine E., Delimpasi G., Hsaio H.P., Keil M., Heyerdahl S., Matyakhina L., Libe R., Fratticci A., Kirschner L.S., Cramer K., Gailliard R.C., Bertagna X., Carney J.A., Bertherat J., Bossis I., Stratakis C.A. A genome-wide scan identifies mutation in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat. Genet. 2006, 38(7):794-800.
78. Horvath A., Mericq V., Stratakis C.A. A mutation in PDE8B, a cyclic AMP - specific phosphodiesterase in adrenal hyperplasia (Letter). New Eng. J. Med. 2008, 358:750-752.
79. Horvath J.E., Groot K., Schally A.V. Growth hormone-releaseing hormone stimualtes cAMP release in superfused rat pituitary cells. Proc. Natl. Acad. Sci. USA 1995, 92(6):1856-1860.
80. Houslay M.D., Milligan G. Tailoring cAMP signalling responses through isoform multiplicity. Trends Biochem. Sci. 1997, 22:217-224.
81. Hubina E., Nanzer A.M., Hanson M.R., Ciccarelli E., Losa M., Cala D., Papotti M., Terreni M.R., Khalaf S., Jordan S., Czirjak S., Hanzely Z., Nagy G.M., Goth M.I., Grossman A., Korbonitz M. Somatostatin analogue stimulates p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur. J. Endocrinol. 2006, 155:371-379.
82. Igreja S., Chahal H.S., King P., Bolger G.B., Srirangalingam U., Guasti L., Chapple J.P., Trivellin G., Gueorguiev M., Guegan K., Stals K., Khoo B., Kumar A.V., Ellard S., Grossman AB., Korbonits M., International FIPA Consortium Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum. Mutat. 2010, 31:950-960.
83. Jiang L.I., Collins J., Davis R., Fraser I.D., Sternweis P.C. Regulation of cAMP responses by the G12/13 pathway converges on adenylate cyclase VII. J. Biol. Chem. 2008, 283:23429-23439.
84. Jiang L.I., Collins J., Davis R., Lin K.M., DeCamp D., Roach T., Hsueh R., Rebres R.A., Ross E.M., Taussig R., Fraser I., Sternweis P.C. Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway. J. Biol. Chem. 2007, 282:10576-10584.
85. Johannessen M., Delghandi M.P., Moens U. What turns CREB on?. Cell. Signal. 2004, 16(11):1211-1227.
86. Jordan S., Lidhar K., Korbonits M., Lowe D.G., Grossman A.B. Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur. J. Endocrinol. 2000, 143(1):R1-R6.
87. Kanno Y., Takane Y., Izawa T., Nakahama T., Inouye Y. The inhibitory effect of aryl hydrocarbon receptor repressor (AhRR) on the growth of human breast cancer MCF-7 cells. Biol. Pharm. Bull. 2006, 29(6):1254-1257.
88. Karga H.J., Alexander J.M., Hedley-White E.T., Klibanski A., Jameson J.L. Ras mutations in human pituitary tumors. J. Clin. Endocrinol. Metab. 1992, 74(4):914-919.
89. Kirschner L.S., Carney J.A., Pack S.D., Taymans S.E., Giatzakis C., Cho Y.S., Cho-Chung Y.S., Stratakis C.A. Mutations of the gene encoding the protein kinase A type 1-alpha regulatory subunit in patients with Carney Complex. Nat. Genet. 2000, 26(1):89-92.
90. Kits K.S., Mansvelder H.D. Regulation of exocytosis in neuroendocrine cells: spatial organization of channels and vesicles, stimulus-secretion coupling, calcium buffers and modulation. Brain Res. 2000, 33(78-94):2000.
91. Kim D.W., Gazouria L., Quadri S.A., Romieu-Mourez R.I., Sherr D.H. The RelA NF-kB subunit and the aryl hydrocarbon receptor (AhR). cooperate to transactivate the c-myc promoter in mammary cells. Oncogene. 2000, 19:5498-5506.
92. Klein E.A., Assoian R.K. Transcriptional regulation of the cyclin D1 gene at a glance. J. Cell Sci. 2008, 121:3853-3857.
93. Koch B.D., Dorflinger L.J., Schonnbrunn A. Pertussis toxin blocks both cyclic AMP-mediated and cyclic AMP- independent actions of somatostatin: evidence for coupling of Ni to decreases in intracellular free calcium. J. Biol. Chem. 1985, 260(24):13138-13145.
94. Kremenevskaya, N., Khattak, M.N., Buchfelder, M., 2007. The Involvement of the Wnt/beta-catenin pathway in pituitary adenomas. Abstract Presented at the 58th Annual Meeting of the German Society of Neurosurgery.
95. Kuryshev Y.A., Childs G.V., Ritchie A.K. Corticotropin-releasing hormone stimulation of Ca2+ entry in corticotropes in partially dependant on protein kinase A. Endocrinology 1995, 136(9):3925-3935.
96. Landis C.A., Masters S.B., Spada A., Pace A.M., Bourne H.R., Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989, 340(6236):692-696.
97. Landis C.A., Harsh G., Lyons J., Davis R.L., McCormick F., Bourne H.R. Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein. J. Clin. Endocrinol. Metab. 1990, 71:1416-1420.
98. Lania A.G., Mantovani G., Ferrero S., Pellegrini C., Bondioni S., Peverelli E., Braidotti P., Locatelli M., Zavanone M.L., Ferrante E., Bosari S., Beck-Peccoz P., Spada A. Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase a regulatory subunit 1A protein. Cancer Res. 2004, 64:9193-9198.
99. Leontiou C.A., Gueorguiev M., van der Spuy J., Quinton R., Lolli F., Hassan S., Chahal H.S., Igreja S.C., Jordan S., Rowe J., Stolbrink M., Christian H.C., Wray J., Bishop-Bailey D., Berney D.M., Wass J.A.H., Popovic V., Ribiero-Oliveria A., Gadelha M.R., Monson J.P., Akker S.A., Davis J.R.E., Clayton R.N., Yoshimoto K., Iwata T., Matsuna A., Eguchi K., Musat M., Flanagan D., Peters G., Bolger G.B., Chapple J.P., Frohman L.A., Grossman A.B., Korbonits M. The role of the AIP gene in familial and sporadic pituitary adenomas. J. Endocrinol. Metab. 2008, 93(6):2390-2401.
100. Li Y., Ndubuka C., Rubin C.S. A kinase anchor protein 75 targets regulatory (RII) subunits of cAMP-dependent protein kinase II to the cortical actin cytoskeleton in non-neuronal cells. J. Biol. Chem. 1996, 271:16862-16869.
101. Libe R., Frattacci A., Coste J., Tissier F., Horvath A., Ragazzon B., Rene-Corail F., Groussin L., Bertagna X., Raffin-Sanson M.L., Stratakis C.A., Bertherat J. Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin. Cancer Res. 2008, 14(12):4016-4024.
102. Libe R., Horvath A., Vezzosi D., Fratticci A., Coste J., Perlemoine K., Ragazzon B., Guillaud-Bataille M., Groussin L., Clauser E., Raffin-Sanson M.L., Siegel J., Moran J., Drori-Herishanu L., Faucz F.R., Lodish M., Nesterova M., Bertagna X., Bertherat J., Stratakis C.A. Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. J. Clin. Endocrinol. Metab. 2011, 96:E208-E214.
103. Lin P., Hu S.W., Chang T.H. Correlation between Gene Expression of the Aryl Hydrocarbon Receptor (AhR), Hydrocarbon Receptor Nuclear Translocator (Arnt), Cytochromoes P4501A1 (CYP1A1) and 1B1 (CYP1B1), and Inducibility of CYP1A1 and CYP1B1 in Human Lymphocytes. Toxicol. Sci. 2003, 71:20-26.
104. Logue J.S., Scott J.D. The integration of the Wnt and cAMP Signalling pathways by AKAP220. FASEB J. 2008, 22(822):2.
105. Lowndew J.M., Gupta S.K., Osawa S., Johnson G.L. GTPase-deficient G alpha i1 oncogene gip2 inhibits adenylyl cyclase and attenuates receptor-stimulated phospholipase A1 activity. J. Biol. Chem. 1991, 266(22):14193-14197.
106. Lu C., Willingham M.C., Furuya F., Cheng S.Y. Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors. Endocrinology 2008, 149(7):3339-3345.
107. Lui Y.F., Jakobs K.H., Rasenick M.M., Albert P.R. G protein specificity in receptor - effector coupling. J. Biol. Chem. 1994, 269:13880-13886.
108. Luo J., Chen J., Deng Z.L., Luo X., Song W.X., Sharff K.A., Tang N., Haydon R.C., Luu H.H., He T.C. Wnt signaling and human diseases: what are the therapeutic implications?. Lab. Invest. 2007, 87:97-103.
109. Lussier B.T., French M.B., Moor B.C., Kraicer J. Free intracellular Ca2+ concentration and growth hormone (GH) release from purified rat somatotrophs. III. Mechanism of action of GH-releasing factor and somatostatin. Endocrinology 1991, 128:592-603.
110. Lyons J., Landis C.A., Harsh G., Vallar L., Grunewald K., Feichtinger H., Duh Q.Y., Clark O.H., Kawasaki E., Bourne H.R., McCormick F. Two G protein oncogenes in human endocrine tumors. Science 1990, 249(4969):655-659.
111. Machiavelli G.A., Rivolta C.M., Artese R., Basso A., Burdman J.A. Expression of c-myc and c-fos and binding sites for estradiol and progesterone in human pituitary tumors. Neurol. Res. 1998, 20(8):709-712.
112. Mavrakis M., Lippincott-Schwartz J., Stratakis C.A., Bossis I. Depletion of type IA regulatory subunit (RIalpha) of protein kinase A (PKA) in mammalian cells and tissues activates mTOR and causes autophagic deficiency. Hum. Mol. Genet. 2006, 15:2962-2971.
113. Mayr B., Montminy M. Transcriptional Regulation of the Phosphorylation-dependant factor CREB. Mol. Cell. Biol. 2001, 2:599-607.
114. Mazzucchelli C., Sassone-Corsi P. The inducible cyclic adenosine monophosphate early repressor (ICER) in the pituitary intermediate lobe: role in the stress response. Mol. Cell. Endocrinol. 1999, 155:101-113.
115. MacKenzie S.J., Baillie G.S., McPhee I., Bolger G.B., Houslay M.D. ERK2 MAP kinase binding, phosphorylation and regulation of PDE4D cAMP specific phosphodiesterases: The involvement of C-terminal docking sites and N-terminal UCR regions. J. Biol. Chem. 2000, 275:16609-16617.
116. Melmed S., Conn P.M. Endocrinology: Basic and Clinical Principles 2005, Humana Press, New York. second ed.
117. Melmed S. Acromegaly pathogenesis and treatment. J. Clin. Invest. 2009, 119(11):3189-3202.
118. Miyakoshi T., Takei M., Kajiya H., Egashira N., Takekoshi S., Teramoto A., Osamura R.Y. Expression of Wnt4 in human pituitary adenomas regulates activation of the beta-catenin - independent pathway. Endocr. Pathol. 2008, 19(4):261-273.
119. Miyata A., Arimura A., Dahl R.R., Minamino N., Uehara A., Jiang L., Culler M.D., Coy D.H. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 1989, 164:567-574.
120. Molina C.A., Foulkes N.S., Lalli E., Sassone-Corsi P. Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell 1993, 75:875-886.
121. Mantovani G., Bondioni S., Ferrero S., Gamba B., Ferrante E., Peverelli E., Corbetta S., Locatelli M., Rampini P., Beck-Peccoz P., Spadam A., Lania A.G. Effect of cyclic adenosine 3',5'-monophospahte/protein kinase a pathway on markers of cell proliferation in nonfunctioning pituitary adenomas. J. Clin. Endocirnol. Metab. 2005, 90(12):6721-6724.
122. Moore M.J., Kanter J.R., Jones K.C., Taylor S.S. Phosphorylation of the catalytic subunit of Protein Kinase A: Autophosphorylation versus phosphorylation by phosphoinositide -dependant kinase -1. J. Biol. Chem. 2002, 277:47878-47884.
123. Moreno C.S., Evans C., Zhan X., Okor M., Desiderio D.M., Oyesiku N.M. Novel molecular signaling and Classification of human Clinically nonfunctional pituitary adenomas identified by expression profiling and proteomic analysis. Cancer Res. 2005, 65(22):10214-10222.
124. Munemura M., Cote T.E., Tsuruta K., Eskay R.L., Kebabian J.W. The dopamine receptor in the intermediate lobe of the rat pituitary gland: pharmacological characterization. Endocrinology 1980, 107:1676-1683.
125. Murakami Y., Koshimura K., Yamauchi K., Nishiki M., Tanaka J., Furuya H., Miyake T., Kato Y. Pituitary adenylate cyclase activating polypeptide (PACAP) stimulates growth hormone release from GH3 cells through type II PACAP receptor. Regul. Pept. 1995, 56:35-40.
126. Musat M., Vax V.V., Borboli N., Gueoguiev M., Bonner S., Korbonits M., Grossman A.B. Cell cycle dysregulation in pituitary oncogenesis. Front Horm. Res. 2004, 32:34-62.
127. Nadella K.S., Kirschner L.S. Disruption of protein kinase a regulation causes immortalization and dysregulation of D-type cyclins. Cancer Res. 2005, 65(22):10307-10315.
128. Nakata A., Urano D., Fujii-Kuriyama Y., Mizuno N., Tago K., Itoh H. G-protein signalling negatively regulates the stability of aryl hydrocarbon receptor. EMBO Rep. 2009, 10:622-628.
129. Navilgio S., Caraglia M., Abbruzzese A., Chiosi E., Di Gesto D., Marra M., Romano M., Sorrentino A., Sorvillo L., Spina A., Illiano G. Protein kinase A as a biological target in cancer therapy. Expert. Opin. Ther. Targets 2009, 13(1):83-92.
130. Nussey S., Whitehead S. Endocrinology: An Integrated Approach 2001, BIOS Scientific Publishers, Oxford.
131. Oesch-Bartlomowicz B., Huelster A., Wiss O., Antoniou-Lipfert P., Dietrcih C., Arand M., Weiss C., Bockamp E., Oesch F. Aryl hydrocarbon receptor activation by cAMP vs dioxin: divergent signaling pathways. Proc. Natl. Acad. Sci. USA 2005, 102(26):9218-9223.
132. Oesch-Bartlomowicz B., Oesch F. Role of cAMP in AHR signalling. Biochem. Pharmacol. 2009, 77(4):624-641.
133. Ohtsuka T., Shimizu K., Yamamori B., Kuroda S., Takai Y. Activation of brain B-Raf protein kinase by Rap1B small GTP-binding protein. J. Biol. Chem. 1996, 271:1258-1261.
134. Oka H., Jin L., Reubi J.C., Qian X., Scheithauer B.W., Fujii K., Kameva T., Lloyd R.V. Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas. Am. J. Pathol. 1998, 153:1787-1796.
135. Omori K., Kotera J. Overview of PDEs and their regulation. Circ. Res. 2007, 100(3):309-327.
136. Parma J., Duprez L., Van Sande J., Cochaux P., Gervy C., Mockel J., Dumont J., Vassart G. Somatic mutation in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993, 365:649-651.
137. Peri A., Conforti B., Baglioni-Peri S., Luciani P., Cioppi F., Buci L., Corbetta S., Ballare E., Serio M., Spada A. Expression of cyclic adenosine 30,50-monophosphate (cAMP)-responsive element binding protein and inducible-cAMP early represser genes in growth hormone-secreting pituitary adenomas with or without mutations of the Gsa gene. J. Clin. Endocrlnol. Metab. 2001, 86:2111-2117.
138. Persani L., Borgata S., Lania A., Filopanti M., Mantovani G., Conti M., Spada A. Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gsα mutations. J. Clin. Endocrinol. Metab. 2001, 86(8):3795-3800.
139. Pertuit M., Barlier A., Enjalbert A., Gerard Singalling pathway altrations in pituitary adenomas: involvement of Gsα, cAMP and mitogen-activated protein kinases. J. Endocrinol. 2009, 21:269-877.
140. Polakis P. Wnt signaling and cancer. Genes Devel. 2000, 14:1837-1851.
141. Porterfield S. Endocrine Physiology 2001, Mosby, USA. second ed.
142. Prochazkova J., Kabatkova M., Bryja V., Umannova L., Bernatik O., Kozubik A., Machala M., Vondracek J. The interplay of the aryl hydrocarbon receptor and B-catenin alters both AHR-dependant transcription and Wnt/B-catenin signaling in liver progenitors. Toxicol. Sci. 2011, 122(2):349-360.
143. Radcliff R.P., Lookingland K.J., Chapin L.T., Tucker H.A. Pituitary adenylate cyclase-activating polypeptide induces secretion of growth hormone in cattle. Domest. Anim. Endocrinol. 2001, 21:187-196.
144. Raghanan R., Harrison D., Ince P.G., James R.A., Daniels M., Birch P., Caldwell G.I., Kendall-Taylor P. Oncoprotein immunoreactivity in human pituitary tumours. Clin. Endocrinol. 1994, 40(1):117-126.
145. Ramirez J.L., Castano J.P., Torronteras O.R., Martinez-Fuentes A.J., Frawley L.S., Garcia-Navarro S., Gracia-Navarro F. Growth hormone (GH)-Releasing Factor differentially activates cyclic adenosine 3',5'-monophosphate- and Inositol phosphate-dependant pathways to stimulate GH release in two porcine somatotrophe subpopulations. Endocrinology 1999, 140(4):1752-1759.
146. Ramirez J.L., Gracia-Navarro F., Garcia-Navarro S., Torronteras R., Malagon M.M., Castano J.P. Somatostatin stimulates GH secretion in two porcine somatotrophe subpopulations through a cAMP-dependant pathway. Endocrinology 2002, 143(3):889-897.
147. Razavi R., Ramos J.C., Yehia G., Schlotter F., Molina C.A. ICER-IIg is a tumor suppressor that mediates the anti-proliferative activity of cAMP. Oncogene 1998, 17:3015-3019.
148. Robberecht P., Vertongen P., Velkeniers B., de Neefs P., Vergani P., RAftopoulos C., Brotchi J., Hooghe-Peteres E.L., Cristophe J. Receptors for pituitary adenylate cyclase activating peptides in human pituitary adenomas. J. Clin. Endocrinol. Metab. 1993, 77(5):1235-1239.
149. Robinson-White A., Hundley T.R., Shiferaw M., Bertherat J., Sandrini F., Stratakis C.A. Protein kinase-A activity in PRKAR1A-mutant cells, and regulation of mitogen activated protein kinases ERK1/2. Hum. Mol. Genet. 2003, 12(13):1475-1484.
150. Rodbell M. The complex regulation of receptor coupled G-proteins. Adv. Enzyme Regul. 1997, 37:427-435.
151. Romano D., Magalon K., Pertuit M., Rasolonjanahary R., Barlier A., Enjalbert A., Gerard C. Conditional overexpression of the wild-type Gs alpha as the GNAS oncogene initiates chronic extracellular regulated kinase 1/2 activation and hormone hypersecretion in pituitary cell lines. Endocrinology 2007, 148(6):2973-2983.
152. Saeger W., Schreiber S., Ludecke D.K. Cyclins D1 and D3 and Topoisomerase IIa in Inactive Pituitary Adenomas. Endocr. Pathol. 2001, 12(1):39-47.
153. Sakai N., Kim K., Sanno N., Yoshida D., Teramoto A., Shibasaki T. Elevation of growth hormone receptor messenger ribonucleic acid expression in growth hormone - secreting pituitary adenoma with Gsalpha protein mutation. Neurol. Med. Chir. (Tokyo). 2008, 48(11):481-487.
154. Sands W.A., Palmer T.M. Regulating gene transcription in response to cyclic AMP elevation. Cell. Signal. 2008, 20(3):460-466.
155. Sedej S., Rose T., Rupnik M. CAMP increases Ca2+-dependant exocytosis through both PKA and Epac2 in mouse melanotrophs from pituitary tissue slices. J. Physiol. 2005, 567(3):799-813.
156. Shaywitz A.J., Greenberg M.E. CREB: a stimulus induced transcription factor activated by a diverse array of extraceullular signals. Annu. Rev. Biochem. 1999, 68:821-861.
157. Shi Y., Tang D., Deng J., Su C. Detection of GNAS oncogene in growth hormone-secreting pituitary adenomas and the study of clinical characteristics of acromegalic patietns with GNAS-positive pituitary tumors. Chin. Med. J. (Engl.) 1998, 111(10):891-894.
158. Shtutman M., Zhurinsky J., Simcha I., Albanese C., D'Amico M., Pestell R., Ben-Ze'ev A. The cyclin D1 gene is a target of the B-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA 1999, 96:5522-5527.
159. Sikdar S.K., Kreft M., Zorec R. Modulation of the unitary exocytic event amplitude by cAMP in rat melanotrophs. J. Physiol. 1998, 511:851-859.
160. Spada A., Lania A., Mantovani S. Cellular abnormalities in pituitary tumors. Metabolism 1996, 45:46-48.
161. Suzuki S., Yamamoto I., Arita J. Mitogen-activated protein kinase-dependant stimulation of proliferation of rat lactotrophs in culture by 3',5'-cyclic adenosine monophosphate. Endocrinology 1999, 140(6):2850-2858.
162. Suzuki A., Ozono K., Kubota T., Kondou H., Tachikawa K., Michigami T. PTH/cAMP/PKA signalling facilitates canonical Wnt signalling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells. J. Cell. Biochem. 2008, 104(1):304-317.
163. Tasken K.A., Collas P., Kemmner W.A., Witczak O., Contri M., Tasken K. Phosphodiesterase 4D and protein kinase a type II constitute a signalling unit in the centrosomal area. J. Biol. Chem. 2001, 276:21999-22002.
164. Taurin S., Sandbo N., Qin Y., Browning D., Dulin N.O. Phosphorylation of beta-catenin by cyclic AMP-dependant protein kinase. J. Biol. Chem. 2006, 281(15):9971-9976.
165. Tordjman K., Stern N., Ouaknine G., Yossiphov Y., Razon N., Nordenskjold M., Friendlan E. Activating mutations of the Gs alpha-gene in non-functioning pituitary tumors. J. Clin. Endocrinol. Metab. 1993, 77:765-769.
166. Torii K., Nishizawa K., Kawasaki A., Yamashita Y., Katada M., Ito M., Nishimoto I., Terashita K., Aiso S., Matsuoka M. Anti-apoptotic action of Wnt5a in dermal fibroblasts is mediated by the PKA signaling pathways. Cell. Signal. 2008, 20(7):1256-1266.
167. Trivellin G., Korbonitz M. AIP and its interacting partners. J. Endocrinol. 2011, 210:137-155.
168. Turner H.E., Nagy Z., Sullivan N., Esiri M.M., Wass J.A. Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clin. Endocrinol. (Oxf.) 2000, 53(3):337-344.
169. Vallar L., Spada A., Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987, 330(6148):556-568.
170. Vaudry D., Gonzalez B.J., Basille M., Fournier A., Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev. 2000, 52(2):269-324.
171. Vierimaa O., Goergitsi M., Lehtonen R., Vahteristo P., Kokko A., Raitila A., Tuppurainen K., Ebeling T.M.L., Salmela P.I., Paschke R., Gundogdu S., De Menis E., Makinen M.J., Launonen V., Karhu A., Aaltonen L.A. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312:1128-1230.
172. Vigh S., Arimura A., Gottschall P.E., Kitada C., Somogyvari-Vigh A., Childs G.V. Cytochemical characterization of anterior pituitary target cells for the neuropeptide, pituitary adenylate cyclase-activating polypeptide (PACAP) using biotinylated ligands. Peptides 1993, 14:59-65.
173. Vitali E., Peverelli E., Giardino E., Locatelli M., Lasio G.B., Beck-Peccoz P., Spada A., Lania A.G., Mantovani G. Cyclic adenosine 3',5'-monophosphate (cAMP) exerts proliferative and anti-proliferative effects in pituitary cells of different types by activating both cAMP-dependant protein kinase A (PKA) and exchange proteins directly activated by cAMP (Epac). Mol. Cell. Endocrinol. 2014, 383:193-202.
174. Vossler M.R., Yao H., York R.D., Pan M.G., Rim C.S., Stork P.J. CAMP activates MAP kinase and Elk-1 through a B-Raf and Rap-1 dependant pathway. Cell 1997, 89:73-82.
175. Weinstein L.S., Shenker A., Gejman P.V., Merino M.J., Friedman E., Spiegel A.M. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N. Engl. J. Med. 1991, 325(24):1688-1695.
176. Withers D.J. Signalling pathways involved in the mitogenic effects of cAMP. Clin. Sci. (Lond.) 1997, 92(5):445-451.
177. Woloschak M., Robert sJ.L., Post K. C-myc, c-fos, and c-myb gene expression in human pituitary adenomas. J. Clin. Endocrinol. Metab. 1994, 79(1):253-257.
178. Yang I., Park S., Ryu M., Woo J., Kim S., Kim J., Kim Y., Choi Y. Characteristics of GNAS-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. Eur. J. Endocrinol. 1996, 134(6):720-726.
179. Yang X., Lee F.Y.G., Wand G.D. Increased Expression of the Gsa enhances activation of the Adenylyl Cyclase Signal transduction cascade. Mol. Endocrinol. 1997, 11(8):1053-1061.
180. Yao H., York R.D., Misra-Press A., Carr D.W., Stork P.J. The cyclic adenosine monophosphate-dependant protein kinase (PKA) is required for the sustained activation of mitogen-activated kinases and gene expression by nerve growth factor. J. Biol. Chem. 1998, 273:8240-8247.
181. Yasufuku-Takano J., Takano K., Takei T., Fukumoto S., Teramoto A., Takakura K., Tamashita N., Fujita T. Heterozygous GNAS mutation renders ion channels of human somatotroph adenoma cells unresponsive to growth hormone-releasing hormone. Endocrinology 1999, 140(5):2018-2026.
182. Yasufuku-Takano J., Takano K., Morita K., Takakura K., Teramoto A., Fujita T. Does the prevalence of GNAS mutations in GH-secreting pituitary adenomas differ geographically or racially? Prevalence of GNAS mutations in Japanese patients revisited. Clin. Endocrinol. (Oxf.) 2006, 64(1):91-96.
183. Yin Z., Williams-Simons L., Parlow A.F., Asa S., Kirschner L.S. Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis. Mol. Endocrinol. 2008, 22(2):380-387.
184. Yu R., Bonert V., Saporta I., Raffel L.J., Melmed S. Aryl hydrocarbon receptor Interacting Protein Variants in Sporadic Pituitary Adenomas. J. Clin. Endocrinol. Metab. 2006, 91(12):5126-5129.
185. Zudaire E., Cuesta N., Murty V., Woodson K., Adams L., Gonzales N., Martinez A., Narayan G., Kirsch I., Franklin W., Hirsch F., Birrer M., Cuttitta F. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J. Clin. Invest. 2008, 118(2):640-650.